Artelo Biosciences, Inc.
ARTL
$5.98
-$0.21-3.39%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 24.65% | -24.70% | -10.27% | -175.62% | -32.39% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -61.11% | -- | -- | -- | -- |
| Total Other Non-Cash Items | 237.74% | 178.00% | 850.00% | 137.66% | 28.23% |
| Change in Net Operating Assets | -226.86% | 95.48% | -147.15% | -513.50% | 913.82% |
| Cash from Operations | -879.18% | 25.42% | -13.40% | -349.61% | 75.08% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -62.40% | -105.88% | -- |
| Cash from Investing | -- | -- | -62.40% | -105.88% | -- |
| Total Debt Issued | -100.00% | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -83.50% | -- | 2,987.72% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -158.59% | -- | 2,719.30% | -- | -- |
| Foreign Exchange rate Adjustments | 22.22% | -20.00% | 55.56% | -1,150.00% | 1,900.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -560.23% | 707.60% | 44.53% | -109.95% | 520.38% |